Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolynovoCALZF 74 EV-to-EBITDA is 92.07 as of Jul. 30, 2026. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $2.14 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Polynovo ranks worse than 94.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Polynovo's enterprise value is $416.26 Mil.
Polynovo's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $4.52 Mil. Therefore, Polynovo's EV-to-EBITDA for today is 92.07.
The historical rank and industry rank for Polynovo's EV-to-EBITDA or its related term are showing as below:
CALZF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -797.56 Med: -50.39 Max: 2253.23
Current: 85.39
During the past 13 years, the highest EV-to-EBITDA of Polynovo was 2253.23. The lowest was -797.56. And the median was -50.39.
CALZF's EV-to-EBITDA is ranked worse than 94.71% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.265
vs CALZF: 85.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Polynovo (OTCPK:CALZF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Polynovo's share price for today is $0.56.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Polynovo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Polynovo's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Polynovo's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Polynovo's EV-to-EBITDA falls into.
Polynovo's current Enterprise Value is $416.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Polynovo's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $4.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo (CALZF) has a EV-to-EBITDA of 92.07 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Polynovo. According to the industry distribution chart, Polynovo ranks #483 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 94.7%.
Is Polynovo's EV-to-EBITDA too high?
Polynovo's current EV-to-EBITDA is 92.07. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.27. Polynovo's value of 92.07 is 545.4% above this industry median. Based on the distribution chart, Polynovo ranks #483 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #483 out of 510 companies for EV-to-EBITDA. This places Polynovo in the lower half of its industry. The industry median EV-to-EBITDA is 14.27. Polynovo's value of 92.07 is 545.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.27, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current EV-to-EBITDA of 92.07 is 545.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Polynovo. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current EV-to-EBITDA is 92.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.14, compared to a current price of $0.56 — trading 73.8% below its estimated fair value. The current EV-to-EBITDA is 92.07 and 545.4% above the Medical Devices & Instruments industry median of 14.27. Polynovo's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Polynovo (CALZF), the current EV-to-EBITDA is 92.07 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.56 is trading 73.8% below its estimated GF Value™ of $2.14.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
EV-to-EBITDA: 92.07
GF Value™: $2.14 vs. price of $0.56 (73.8% below fair value)
Industry Position: 545.4% above the Medical Devices & Instruments median (#483 of 510)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score
Get the complete analysis for CALZF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 
